The 17th ECCO Intensive Advanced Course in IBD for residents, fellows in gastroenterology and junior faculty will take place in Copenhagen, Denmark, on March 6-7, 2019 just prior to our next Congress. We are pleased to inform you that the Preliminary programme of this course is already available.
Since ECCO wants to make this course as attractive as possible for the participants, we limit the general number of participants for each ECCO Member Country to 2 in order to ensure a more interactive atmosphere. Three seats will be open for countries with a population of over 50 million (this includes: Italy, France, Germany, Russia, UK and Turkey). We do however encourage you to send in 1-2 back-up nominees in the event of cancelations.
Minimum criteria for nominees:
ECCO Member status (2019)
- Trainees at least in their third year with preferably one year GI experience
- Should demonstrate a sufficient level of English to follow the course
- Please submit a letter of application emphasising why you should be selected along with a CV
- Although the deadline from ECCO is the 7th September, please submit your application to the BSG by Friday 24th August.
- Applications should be sent to firstname.lastname@example.org
"Already in 2014 Copenhagen hosted a very successful ECCO Congress and it is with great anticipation that we return to the city and to the Bella Center. In the last few years ECCO congress has become THE major IBD meeting in the world attracting over 6500 participants, offering possibilities for nurses, dietitians, surgeons, gastroenterologists and physicians in the area of IBD to exchange knowledge and participate in a growing spectrum of educational courses and masterclasses. ECCO reaches out to young clinicians and scientists as well and offers an international platform across and beyond Europe to achieve an improvement in the care of patients with IBD in all its aspects.
The main theme of the congress will be “research drives clinical care” as we are witnessing major breakthroughs of innovation due to new drugs hitting the clinic for our patients and many new personalized approaches for individual patient treatments."